Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion

Van T M Nguyen; Iros Barozzi; Monica Faronato; Ylenia Lombardo; Jennifer H. Steel; Naina Patel; Philippa Darbre; Leandro Castellano; Balázs Gyorffy; Laura Woodley; Alba Meira; Darren K. Patten; Valentina Vircillo; Manikandan Periyasamy; Simak Ali; Gianmaria Frige; Saverio Minucci; R. Charles Coombes; Luca Magnani

doi:10.1038/ncomms10044

Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion

Van T M Nguyen, Iros Barozzi, Monica Faronato, Ylenia Lombardo, Jennifer H. Steel, Naina Patel, Philippa Darbre, Leandro Castellano, Balázs Gyorffy, Laura Woodley, Alba Meira, Darren K. Patten, Valentina Vircillo, Manikandan Periyasamy, Simak Ali, Gianmaria Frige, Saverio Minucci, R. Charles Coombes, Luca Magnani

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

Endocrine therapies target the activation of the oestrogen receptor alpha (ERα) via distinct mechanisms, but it is not clear whether breast cancer cells can adapt to treatment using drug-specific mechanisms. Here we demonstrate that resistance emerges via drug-specific epigenetic reprogramming. Resistant cells display a spectrum of phenotypical changes with invasive phenotypes evolving in lines resistant to the aromatase inhibitor (AI). Orthogonal genomics analysis of reprogrammed regulatory regions identifies individual drug-induced epigenetic states involving large topologically associating domains (TADs) and the activation of super-enhancers. AI-resistant cells activate endogenous cholesterol biosynthesis (CB) through stable epigenetic activation in vitro and in vivo. Mechanistically, CB sparks the constitutive activation of oestrogen receptors alpha (ERα) in AI-resistant cells, partly via the biosynthesis of 27-hydroxycholesterol. By targeting CB using statins, ERα binding is reduced and cell invasion is prevented. Epigenomic-led stratification can predict resistance to AI in a subset of ERα-positive patients.

Original language	English
Article number	10044
Journal	Nature Communications
Volume	6
DOIs	https://doi.org/10.1038/ncomms10044
Publication status	Published - Nov 27 2015

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)
Chemistry(all)
Physics and Astronomy(all)

Access to Document

10.1038/ncomms10044

Fingerprint Dive into the research topics of 'Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion'. Together they form a unique fingerprint.

Cite this

Nguyen, V. T. M., Barozzi, I., Faronato, M., Lombardo, Y., Steel, J. H., Patel, N., Darbre, P., Castellano, L., Gyorffy, B., Woodley, L., Meira, A., Patten, D. K., Vircillo, V., Periyasamy, M., Ali, S., Frige, G., Minucci, S., Coombes, R. C., & Magnani, L. (2015). Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion. Nature Communications, 6, [10044]. https://doi.org/10.1038/ncomms10044

Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion. / Nguyen, Van T M; Barozzi, Iros; Faronato, Monica; Lombardo, Ylenia; Steel, Jennifer H.; Patel, Naina; Darbre, Philippa; Castellano, Leandro; Gyorffy, Balázs; Woodley, Laura; Meira, Alba; Patten, Darren K.; Vircillo, Valentina; Periyasamy, Manikandan; Ali, Simak; Frige, Gianmaria ; Minucci, Saverio; Coombes, R. Charles; Magnani, Luca.

In: Nature Communications, Vol. 6, 10044, 27.11.2015.

Research output: Contribution to journal › Article › peer-review

Nguyen, VTM, Barozzi, I, Faronato, M, Lombardo, Y, Steel, JH, Patel, N, Darbre, P, Castellano, L, Gyorffy, B, Woodley, L, Meira, A, Patten, DK, Vircillo, V, Periyasamy, M, Ali, S, Frige, G , Minucci, S, Coombes, RC & Magnani, L 2015, 'Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion', Nature Communications, vol. 6, 10044. https://doi.org/10.1038/ncomms10044

Nguyen, Van T M ; Barozzi, Iros ; Faronato, Monica ; Lombardo, Ylenia ; Steel, Jennifer H. ; Patel, Naina ; Darbre, Philippa ; Castellano, Leandro ; Gyorffy, Balázs ; Woodley, Laura ; Meira, Alba ; Patten, Darren K. ; Vircillo, Valentina ; Periyasamy, Manikandan ; Ali, Simak ; Frige, Gianmaria ; Minucci, Saverio ; Coombes, R. Charles ; Magnani, Luca. / Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion. In: Nature Communications. 2015 ; Vol. 6.

@article{e6875d6aad8549e0bdf6e029ecded0ee,

title = "Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion",

abstract = "Endocrine therapies target the activation of the oestrogen receptor alpha (ERα) via distinct mechanisms, but it is not clear whether breast cancer cells can adapt to treatment using drug-specific mechanisms. Here we demonstrate that resistance emerges via drug-specific epigenetic reprogramming. Resistant cells display a spectrum of phenotypical changes with invasive phenotypes evolving in lines resistant to the aromatase inhibitor (AI). Orthogonal genomics analysis of reprogrammed regulatory regions identifies individual drug-induced epigenetic states involving large topologically associating domains (TADs) and the activation of super-enhancers. AI-resistant cells activate endogenous cholesterol biosynthesis (CB) through stable epigenetic activation in vitro and in vivo. Mechanistically, CB sparks the constitutive activation of oestrogen receptors alpha (ERα) in AI-resistant cells, partly via the biosynthesis of 27-hydroxycholesterol. By targeting CB using statins, ERα binding is reduced and cell invasion is prevented. Epigenomic-led stratification can predict resistance to AI in a subset of ERα-positive patients.",

author = "Nguyen, {Van T M} and Iros Barozzi and Monica Faronato and Ylenia Lombardo and Steel, {Jennifer H.} and Naina Patel and Philippa Darbre and Leandro Castellano and Bal{\'a}zs Gyorffy and Laura Woodley and Alba Meira and Patten, {Darren K.} and Valentina Vircillo and Manikandan Periyasamy and Simak Ali and Gianmaria Frige and Saverio Minucci and Coombes, {R. Charles} and Luca Magnani",

year = "2015",

month = nov,

day = "27",

doi = "10.1038/ncomms10044",

language = "English",

volume = "6",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "NLM (Medline)",

}

TY - JOUR

T1 - Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion

AU - Nguyen, Van T M

AU - Barozzi, Iros

AU - Faronato, Monica

AU - Lombardo, Ylenia

AU - Steel, Jennifer H.

AU - Patel, Naina

AU - Darbre, Philippa

AU - Castellano, Leandro

AU - Gyorffy, Balázs

AU - Woodley, Laura

AU - Meira, Alba

AU - Patten, Darren K.

AU - Vircillo, Valentina

AU - Periyasamy, Manikandan

AU - Ali, Simak

AU - Frige, Gianmaria

AU - Minucci, Saverio

AU - Coombes, R. Charles

AU - Magnani, Luca

PY - 2015/11/27

Y1 - 2015/11/27

N2 - Endocrine therapies target the activation of the oestrogen receptor alpha (ERα) via distinct mechanisms, but it is not clear whether breast cancer cells can adapt to treatment using drug-specific mechanisms. Here we demonstrate that resistance emerges via drug-specific epigenetic reprogramming. Resistant cells display a spectrum of phenotypical changes with invasive phenotypes evolving in lines resistant to the aromatase inhibitor (AI). Orthogonal genomics analysis of reprogrammed regulatory regions identifies individual drug-induced epigenetic states involving large topologically associating domains (TADs) and the activation of super-enhancers. AI-resistant cells activate endogenous cholesterol biosynthesis (CB) through stable epigenetic activation in vitro and in vivo. Mechanistically, CB sparks the constitutive activation of oestrogen receptors alpha (ERα) in AI-resistant cells, partly via the biosynthesis of 27-hydroxycholesterol. By targeting CB using statins, ERα binding is reduced and cell invasion is prevented. Epigenomic-led stratification can predict resistance to AI in a subset of ERα-positive patients.

AB - Endocrine therapies target the activation of the oestrogen receptor alpha (ERα) via distinct mechanisms, but it is not clear whether breast cancer cells can adapt to treatment using drug-specific mechanisms. Here we demonstrate that resistance emerges via drug-specific epigenetic reprogramming. Resistant cells display a spectrum of phenotypical changes with invasive phenotypes evolving in lines resistant to the aromatase inhibitor (AI). Orthogonal genomics analysis of reprogrammed regulatory regions identifies individual drug-induced epigenetic states involving large topologically associating domains (TADs) and the activation of super-enhancers. AI-resistant cells activate endogenous cholesterol biosynthesis (CB) through stable epigenetic activation in vitro and in vivo. Mechanistically, CB sparks the constitutive activation of oestrogen receptors alpha (ERα) in AI-resistant cells, partly via the biosynthesis of 27-hydroxycholesterol. By targeting CB using statins, ERα binding is reduced and cell invasion is prevented. Epigenomic-led stratification can predict resistance to AI in a subset of ERα-positive patients.

UR - http://www.scopus.com/inward/record.url?scp=84948679022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948679022&partnerID=8YFLogxK

U2 - 10.1038/ncomms10044

DO - 10.1038/ncomms10044

M3 - Article

AN - SCOPUS:84948679022

VL - 6

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 10044

ER -